MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

0.99 -1

Buy Sell

Overview

Share price change

24h

Current

Min

0.96

Max

1.01

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+400% upside

Market Stats
By TradingEconomics
Market Cap	-4.6M 121M
Previous open	1.99
Previous close	0.99

News Sentiment

By Acuity

55%

45%

310 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 gru 2025, 22:03 UTC

Major Market Movers

Mining Stocks Slip Near the End of Stellar Year

29 gru 2025, 15:57 UTC

Major Market Movers

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

29 gru 2025, 23:43 UTC

Market Talk

Nikkei May Decline; Yen in Focus -- Market Talk

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Operate From Singapore

29 gru 2025, 23:38 UTC

Acquisitions, Mergers, Takeovers

Manus: Will Continue to Sell, Operate Product Subscription Service Through App, Website

29 gru 2025, 23:37 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Integrate Manus Service Into Products

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Will Continue to Operate, Sell Manus Service

29 gru 2025, 23:36 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms: Manus's Talent to Join Team to Deliver General-Purpose Agents Across Consumer, Business Products

29 gru 2025, 23:35 UTC

Acquisitions, Mergers, Takeovers

Manus to Join Meta Platforms

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Raise Values Kraken at US$8.65 Billion

29 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Origin: Octopus Targeting Kraken Separation by Mid 2026

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Rezoning Will Allow for Range of Commercial, Industrial Development Uses

29 gru 2025, 21:31 UTC

Acquisitions, Mergers, Takeovers

BlueScope Also Says Land Adjacent to Port Kembla Steelworks Rezoned to Special Purpose

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin's Kraken Stake to Remain at 22.7%

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin Will Continue to Hold Its 22.7% Interest in Octopus

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Guidance Reflects Sustained Strength of Operating Performance in Recent Months

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

Origin: Additional Interest Offsets Dilution From Raise

29 gru 2025, 21:30 UTC

Acquisitions, Mergers, Takeovers

BlueScope Doesn't Expect Material Impact on 1H Guidance Range

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

Origin Waiving Australia Exclusivity to Kraken in Exchange for Additional 1.5% Equity Interest

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale for A$76 Million Consideration

29 gru 2025, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Expects to Complete Property Sale in 2H of FY 2026

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Selling Residentially Zoned Land in West Dapto to Large Homebuilder

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken's Raise Paves Way for Separation From Octopus Energy

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Origin: Kraken to Raise Total US$1 Billion From New, Existing Investors

29 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Exchanges Contracts for Sale of 33 Hectares of Land in West Dapto

29 gru 2025, 21:27 UTC

Acquisitions, Mergers, Takeovers

Origin Energy to Invest US$140M in Kraken's Standalone Equity Raise

29 gru 2025, 20:22 UTC

Market Talk

Oil Rebounds As Russia-Ukraine War Seen Continuing -- Market Talk

29 gru 2025, 20:14 UTC

Market Talk

U.S. Natural Gas Futures Rise As Front Month Expires -- Market Talk

29 gru 2025, 20:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific--Norfolk Southern Merger Targets Trucking Market Share -- Barrons.com

29 gru 2025, 17:36 UTC

Market Talk

U.S. Natural Gas Inventories Swing to Deficit Vs. 5-Year Average -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

400% upside

12 Months Forecast

Average 5 USD 400%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

310 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.